Primary and secondary endpoints
SECONDARY
For the placebo-controlled period of this study, the primary endpoint was the incidence of AEs and SAEs. The secondary endpoints were (1) the change in the CDR-SB score from baseline over time at week 78, and (2) the incidence of anti-gosuranemab serum antibody responses over time up to week 90.